X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (99596) 99596
Book Chapter (342) 342
Dissertation (129) 129
Conference Proceeding (54) 54
Book / eBook (50) 50
Publication (37) 37
Newspaper Article (10) 10
Book Review (9) 9
Web Resource (9) 9
Government Document (8) 8
Magazine Article (6) 6
Paper (4) 4
Journal / eJournal (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62289) 62289
animals (44024) 44024
mice (32532) 32532
cell line, tumor (30859) 30859
cancer (28466) 28466
oncology (27518) 27518
antineoplastic agents - pharmacology (23417) 23417
antitumor-activity (21865) 21865
xenograft model antitumor assays (20859) 20859
female (20697) 20697
apoptosis (20188) 20188
drug screening assays, antitumor (20188) 20188
chemistry, medicinal (16350) 16350
cell proliferation - drug effects (15574) 15574
pharmacology & pharmacy (14797) 14797
antitumor activity (13897) 13897
male (13641) 13641
biochemistry & molecular biology (12999) 12999
tumors (12922) 12922
antineoplastic agents - chemistry (12783) 12783
mice, nude (12306) 12306
cytotoxicity (11469) 11469
apoptosis - drug effects (11459) 11459
structure-activity relationship (11234) 11234
expression (10179) 10179
analysis (9569) 9569
chemotherapy (9500) 9500
molecular structure (9227) 9227
in-vitro (9068) 9068
antineoplastic agents - chemical synthesis (9060) 9060
dose-response relationship, drug (8894) 8894
tumor cells, cultured (8481) 8481
chemistry, organic (7912) 7912
care and treatment (7895) 7895
cell survival - drug effects (7802) 7802
proteins (7617) 7617
antitumor agents (7549) 7549
mice, inbred balb c (7513) 7513
cells (7393) 7393
research (7363) 7363
anticancer properties (7269) 7269
chemistry, multidisciplinary (7166) 7166
antitumor (6959) 6959
inhibition (6716) 6716
derivatives (6648) 6648
cell biology (6492) 6492
growth (6401) 6401
metastasis (6336) 6336
antineoplastic agents - therapeutic use (6123) 6123
breast cancer (6014) 6014
cancer therapies (6009) 6009
cell proliferation (5998) 5998
activation (5983) 5983
health aspects (5894) 5894
immunotherapy (5639) 5639
therapy (5630) 5630
in-vivo (5353) 5353
gene expression (5291) 5291
neoplasms - drug therapy (5278) 5278
medicine, research & experimental (5242) 5242
kinases (5170) 5170
toxicity (5121) 5121
cell cycle (5084) 5084
inhibitors (4660) 4660
signal transduction (4614) 4614
immunology (4542) 4542
drugs (4497) 4497
antineoplastic agents, phytogenic - pharmacology (4378) 4378
signal transduction - drug effects (4324) 4324
angiogenesis (4266) 4266
antineoplastic agents (4233) 4233
multidisciplinary sciences (4065) 4065
middle aged (4048) 4048
medicine (4018) 4018
flow cytometry (3960) 3960
breast-cancer (3918) 3918
phosphorylation (3865) 3865
research article (3813) 3813
disease models, animal (3749) 3749
xenografts (3698) 3698
rats (3617) 3617
nanoparticles (3587) 3587
ligands (3536) 3536
resistance (3503) 3503
antimitotic agents (3474) 3474
mice, scid (3451) 3451
carcinoma (3446) 3446
biotechnology & applied microbiology (3428) 3428
melanoma (3420) 3420
dna (3399) 3399
models, molecular (3374) 3374
drug synergism (3373) 3373
chemistry (3354) 3354
lung cancer (3314) 3314
proliferation (3295) 3295
aged (3281) 3281
genetic aspects (3272) 3272
inhibitory concentration 50 (3259) 3259
drug design (3211) 3211
drug delivery systems (3189) 3189
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (99063) 99063
Japanese (1477) 1477
Chinese (665) 665
German (206) 206
Russian (142) 142
French (140) 140
Portuguese (129) 129
Spanish (109) 109
Korean (77) 77
Polish (42) 42
Croatian (11) 11
Hungarian (8) 8
Czech (7) 7
Italian (5) 5
Slovak (4) 4
Slovenian (3) 3
Breton (2) 2
Dutch (2) 2
Serbian (2) 2
Turkish (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Catalan (1) 1
Indonesian (1) 1
Latin (1) 1
Malay (1) 1
Persian (1) 1
Romanian (1) 1
Ukrainian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Chemical Society reviews, ISSN 1460-4744, 2018, Volume 47, Issue 3, pp. 909 - 928
Journal Article
European journal of medicinal chemistry, ISSN 0223-5234, 2015, Volume 96, pp. 491 - 503
Journal Article
Cancer science, ISSN 1347-9032, 2018, Volume 109, Issue 12, pp. 3993 - 4002
.... Here, we investigated the antitumor and immunomodulatory activities of lenvatinib (a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1... 
lenvatinib | sorafenib | immunomodulatory activity | anti‐PD‐1 antibody | hepatocellular carcinoma | anti-PD-1 antibody | CLINICAL-TRIAL | ANGIOGENESIS | MACROPHAGES | CANCER | PEMBROLIZUMAB | ONCOLOGY | GROWTH | PD-1 | TUMOR MICROENVIRONMENT | T-CELLS | Antineoplastic Agents, Immunological - administration & dosage | CD8-Positive T-Lymphocytes - cytology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - administration & dosage | Quinolines - administration & dosage | Quinolines - pharmacology | Carcinoma, Hepatocellular - drug therapy | Carcinoma, Hepatocellular - genetics | Antineoplastic Agents - pharmacology | Carcinoma, Hepatocellular - immunology | Immunocompetence | Single-Cell Analysis | Cell Survival - drug effects | Sorafenib - administration & dosage | Liver Neoplasms - genetics | Immunomodulation | Liver Neoplasms - drug therapy | Liver Neoplasms - immunology | Sorafenib - pharmacology | Antineoplastic Agents, Immunological - pharmacology | Xenograft Model Antitumor Assays | Animals | Sequence Analysis, RNA | Phenylurea Compounds - administration & dosage | CD8-Positive T-Lymphocytes - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Phenylurea Compounds - pharmacology | Viral antibodies | Antimitotic agents | RNA sequencing | Cell death | Analysis | Antibodies | Hepatoma | Antineoplastic agents | T cells | Growth factors | Fibroblast growth factor | Laboratories | CD8 antigen | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Metastasis | Kinases | Macrophages | Cancer therapies | Liver cancer | Ret protein | Lymphocytes | Protein-tyrosine kinase receptors | Fibroblast growth factor receptor 1 | Vascular endothelial growth factor | Protein-tyrosine kinase | Tyrosine | Mortality | Immunodeficiency | Ribonucleic acid--RNA | Monocytes | Thyroid cancer | Immune checkpoint | Response rates | Antitumor activity | Angiogenesis inhibitors | Apoptosis | Tumors | Original
Journal Article
International journal of cancer, ISSN 0020-7136, 2018, Volume 143, Issue 2, pp. 419 - 429
Aneustat (OMN54) is a multivalent, botanical anticancer candidate therapeutic. A recent Phase‐I clinical trial has indicated that it is well tolerated by patients and has immunomodulatory activity... 
immunomodulation | first‐generation PDX model | Aneustat | aerobic glycolysis | lactic acid secretion | first-generation PDX model | LACTIC-ACID | TARGET | PROGNOSIS | BALANCE | NK CELLS | GENE | ONCOLOGY | IMMUNE SURVEILLANCE | MICE | SUPPRESSOR-CELLS | T-CELLS | Small Molecule Libraries - pharmacology | Aerobiosis | Small Molecule Libraries - administration & dosage | Humans | Lactic Acid - metabolism | Immunologic Factors - administration & dosage | Male | Macrophages - cytology | Glycolysis - drug effects | Prostatic Neoplasms - immunology | Xenograft Model Antitumor Assays | Animals | Prostatic Neoplasms - genetics | Cell Differentiation - drug effects | Cell Line, Tumor | Macrophages - drug effects | RAW 264.7 Cells | Cell Proliferation - drug effects | Mice | Gene Expression Regulation, Neoplastic - drug effects | Immunologic Factors - pharmacology | Prostatic Neoplasms - drug therapy | Glucose metabolism | Killer cells | Immune response | Analysis | Immunotherapy | Lactic acid | Diagnosis | Macrophages | Gene expression | Prostate cancer | Cancer | Cell proliferation | Animal models | Phenotypes | Immunomodulation | CD8 antigen | Xenotransplantation | Acidification | Cytotoxicity | Lymphocytes T | Patients | Immunosuppression | Rodents | Xenografts | Glycolysis | In vivo methods and tests | Differentiation | Prostate | Immune system | Cancer Therapy and Prevention
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity... 
MEDICINE, GENERAL & INTERNAL | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | CTLA-4 | LIGAND | BLOCKADE | CLINICAL ACTIVITY | PHASE-I | PD-1 | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Lungs | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2443 - 2454
...), has also shown activity against cancers, including non–small-cell lung cancer. Human cancers harbor numerous genetic and epigenetic alterations, generating neoantigens that are potentially recognizable by the immune system... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | THERAPY | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | MEMBER | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article